AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more effectively, according to preliminary results of a clinical trial.

Avastin is licensed as a cancer drug, where it works by attacking the blood vessels that feed oxygen to tumours. But this mechanism of action means it can also work in wet AMD, which is caused by ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

An oral drug that improves vision in diabetic macular edema (DME) would be a game changer because it would be more ...

Investing.com -- Shares of Tempest Therapeutics Inc (NASDAQ: TPST) climbed 5.3% following the announcement that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its cancer ...

Bevacizumab targets the vascular endothelial growth factor signaling pathway, inhibiting tumor angiogenesis and reshaping the tumor microenvironment, positioning it as a cornerstone in ovarian cancer ...

The KEYNOTE-B96 study evaluated Keytruda in combination with chemotherapy (paclitaxel) with or without bevacizumab in patients with ... Efimosfermin, with its direct antifibrotic mechanism of action, ...

Objective: Alkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed ...